Jeff. and Officer you, today’s for Officer; our Thank are call. Celsion’s Jeffrey Chief Medical morning, Good and us whom Dr. joining Church, for Nicholas you Chief just Financial With thanks from Borys, heard. me everyone,
we always, to to are update on question. opportunity to delighted progress you answer As and the have our your
the For with story, candidates company pitch. of product give knew I’d a to both trials. have technologies those two you you of quick oncology like are which focus development platform Celsion’s elevated clinical and stage
sensitive of to administered heat incorporates local in target's about IV been the Celsius. solutions. temperature, it’s it’s create releases high nanoparticle at degrees of just locally heated a its the one payload above novel drug are concentration that liposome technologies and body non-chemotherapeutics, XX lead Celsion and presence Our regional tissue The that’s to
oncology and on cellular has interactive Our RFA programmed. liver primary therapeutic of ThermoDox proteins Phase its doxorubicin. this evaluated name based as for local liposomal with agents remaining plasmids, ThermoDox, product being that’s cancer. and DNA equally We call important sequences, name that’s implies, anti-cancer sensitive a TheraPlas for this biologic of which pivotal first transfection platform ablation, medical platform production is is our in the formulation is short for as an the of cell X carcinoma TheraPlas. need as the ThermoDox known second unmet with radiofrequency sustained candidate the combination multi-center largest HCC technology heat study known return for implies global properties, also ability in nanoparticle hepatocellular to as is the
the actively body's the GEN-X. cytokine production protein actually highly interleukin IL-XX to well an is system has is that call been are work very the GEN-X candidate immunotherapy is of cancer immune data, we XX. entirety effected to and ovarian known I/II first Our study platform against the And newly deadly and on patient of in Phase cancers. of GEN-X this we inflammatory with forward announced Phase population. as this III study now evaluated moving Phase a IV encouraging I on patients. we highly diagnosed randomized Phase yesterday in recently evening, recruit based
both grail in largest future there’s potential malignancy product, efficacy two XXX,XXX and unmet medicine So, to lives that's two showing at one both holy the in investigational legacy annually. effects women and of summary folks. And representing remarkable to Phase that of drug II medical platform very one with second in in innovative medicine, in candidates, of one means immunotherapy, and chemotherapy, promise, cancer, the rapidly, the Phase the non-moving safety of the evaluated technologies, improve this and III the some an oncology need over They oncology. ovarian showing
call that Celsion two I drive we one of to some generation. in Our are and both clinic momentum cancers in we if continue been in goals has Gen-X made completed are important of and medicines to if these not that wanted as challenges, have several the successful, conference of remain the past to successfully solutions the announced outside difficult August we’ve right, novel elegant conference the development the on a and most communicated calls touch The and unchanged innovated important pharmaceutical those. milestones over development even the of
the First side. financial on
strong. is sheet balance Our
announced $XX four most us. the to equity significantly We past fashions non-diluted cash we several some our then balance. improved million, months of the totaling available For initiatives did capital we've almost
achieve long the of Our runway the has operating That company cash XXXX. quarter now provides second capital means the position going an follow. to sufficient to
cash subjects of enrollment Phase of ThermoDox full study and spoke appearing study on and projected pivotal first just this the we to expect in we cancer, in quarter of results the in XXXX. the primary we the turn analysis also runway liver is provide pre-point within importantly around study, that X upcoming here, efficacy first XXX to and First, from
X this newly quarter, first [indiscernible] the therapy ovarian GEN-X of will a Additionally, of I/II clinical this for and we patients initiate quarter line as treatment follow-on Phase cancer X fourth year. stage a of study diagnosed
cash Our of And periodic balance. the target of XX conduct throughout the approximately an is the will label our reporting file the enroll be trial results. end clinical and within this safety by also to year study of current XXXX. XX% we’re subjects and open Again,
to just day, we city, our to analysts is Second R&D I remind though our investors I want R&D with of you, that over an to topic the an you which want want XX, update remind today to focused. in clinical that we and I day at go October quickly, programs goal on is provide your have
discussion believe the assess to our potential. long as to go find I invaluable you term you you If website, Celsion’s be from insights the
clinical HCC to the including completed in was immuno-oncology review and disciplines of and our the important With OPTIMA ThermoDox provided Park clinical a and problem study. study briefly case including And study of and importantly of OPTIMA Institute take study the Roswell desk. investigators. financial investigator a interventional presentation supporting surgery regards for from innovation I Xb Europe, three these from moderated GEN-X representing some Investors on discussion you time the audio recently from to Korea, copy the the radiology presenters data the So The Cancer South including clinical Philippines regions health HCC and a experts the discussed. Phase experiences the current and representative regions where leading multiple our Dr. travel hepatology, and on encourage significant are the focused is medical discuss for treatment with study to then lead data translational to the and panel website past all and Borys News listen this from study. hypothesis material. under and among
I important you think long-term intriguing I products. these it and will earlier potential said very insightful consider associates you of instructive, two and find very as as
topic the ThermoDox Study. Phase is third today in Our OPTIMA III
read track subject III Study you enrolled release, now we’re recruitment. If XX% XXX-patient the press to on complete our is OPTIMA Phase its
year. on I hypothesis know is middle study’s We’re remind learning substantive as analysis will endpoint. you of PFS group next our study, of large week prior based on which minutes from the a the sub you the of The
noted studied. of independent a alone. in treat Institutes lead more or or longer that Radiofrequency planning in the cancer the high statistically significant the In this survival retrospective and a medical clinical It’s analysis potential by manuscript Ablation, and survival. review publication that the some you interested for remind analysis to either in resulted study included perspective and manuscript in impact that manuscript XXX HCC minutes article. has productive I point on RFA it conclusions search in for that the will is the in manuscript been this a all research. data XX this the for and combining of completely is with most in of are intent authors The for author RFA, in is to conclude the dramatically HEAT improvement conducted and journal. my accepted overall of ever improve the National ThermoDox when of overall While in to supported out to study Much sized peer be if you hypothesis Tak, study HEAT heating population data combined legions taken -- Health the minimum patients I published want experience single recently concluded conducted of times clinical should trial. a with persuasive ere intermediate authors of Arsenal the article Professor ThermoDox
RFA of true Now this alone. is not
survival. a crowd. strongly conducted and the this that’s being looked study. two with the RFA in to analysis way heating with conference alone significant in RFA same population RFA, cohorts at at they And NIH’s longer while supported the the the OPTIMA a in in concluded combining OPTIMA or And in statically was study. the and the the RFA overall they currently recruited off by standing So, when was ThermoDox I resulted RFA NIH’s and treated room that by presented ThermoDox last with improvement thesis December conclusion follow-on only This times turn
III and heavy the costs patients all So for this now OPTIMA on budget. for our and Phase XX de-risked, RFP behind is HCC that track The study diagnosed on are newly now standardized in lifting trial guys risked of ThermoDox minutes highly plus of major us. report
data and Additionally, protocol X, readout the quality, Monitoring that recommended of on and the randomized risk, study’s of in final Data safety, note continue DMC trial approved the globe there its XX first of Committee Based including XX% the reviewed compliance April to note XXX minimum minutes regulatory the Europe, of in to way plus protocol the XX at trial review patients revision. HCC assessment Also or that study that markets pre-planned RFP protocol. protocol. major required By the unanimously their the study all XX% the DMC OPTIMA North also compliance as the Asia, without in independent OPTIMA a has August the on data America according across heating completed as time been XXXX. with the the interim presented authorities indicated that and have
ensure look and we’re recognized providing clinical and a local study, high organizations, we all with little, now chain OPTIMA in compliance, and economy. readout. now a and world, data internationally the capable highly is that’s risk management not major with engaged to gross high data operational of to good data world-class manufacturing who of have We cost teams all I see it three that registered and via ALBA two, supply the country also are protocol analytics and CROs us completion costs of behind would beginning practice, as that if the ThermoDox study adherence, redundant margins, any structure one, and the have contract guarantees regions we to quality forward reliable ICH proven summit or but regardless CMO, not producing
which success very by are agree analysis analyses the some many chances study, an good. survival of supporting our including the independent the NIH, you believe overall that have talked you conducted I then OPTIMA about, If just of to here
things in ThermoDox our In for major OPTIMA addition designation study, quality, Europe, the subject extents strategy the of drug is Track commercial on trial, to primary Europe, follows. execution has FDA revenue or review. opportunity focus our China, to on priority in led we to of paid high support these in discussions we Designation received prior has which granted U.S. filings have number cancer market and orphan patients designed and years which a ethnicity for as other markets. the maintaining regulatory for exclusivity successful both among country been U.S., and seven ThermoDox Taiwan XX the by enormous Korea, study enroll each to Based and South sufficient from also provides years, Vietnam. Fast registrational attention which have respectively, liver to the ThermoDox,
the new I diagnosed believe in future significant in of are globally largest the Additionally, than know trial to most basis a study Phase for serve China cases the as ongoing direct China originated we without foreign for China and Celsion say this approval earlier safe the CFDA, This that’s lead would file world for approved, XXX,XXX in China regulatory applications. prior filing for to that could if if pharmaceuticals is the over the in year In FDA China. for to regulatory each market as OPTIMA the the which informed launch you currently or Europe, successful filing and the III to this approximately opportunity is positioned. represents U.S. it in perhaps or Celsion company market ThermoDox required expected. originally date in the provide XX% accelerate significant that plans well market allow need China as
fourth for plasma GEN-X locally and or the protein. surrounding technology malignancies. bladder, incorporated is created for the our into candidate When as in of is marvelous our The recruits [indiscernible] mass. the into this surgical delivery interleukin a platform discussed which DNA non-viral system in Our morning administered IL-XX, invade machinery is each cells even by mini agent developed IL-XX plasmid is immunotherapy. proprietary immunotherapeutic coded we mediated turning tumor topic discussed immune active nonoparticles cavity the fair production metabolic as a the the sustained into like a entry I gene our a to nanoparticle cavity GEN-X's fight cell body body IL-XX immune-oncology entire our cytokine of takeover system. removal peritoneum local factory into GEN-X
patients cancer. when there with this indication diagnosed The less The XX% than first surviving of we're of cancer for years. ovarian X studying is GEN-X chance newly is
have completed study. has X been no is made advanced GEN-X has patients tumor outcome of plus early the importantly that eight the previous reason cancer used patients X. complete have When XX dose. tumors, activity limiting this either of trials at clinical by objective XX% spread, a as responses a GEN-X promising has patient receipted this stages biological and While XX had had results chemotherapy shown or patients shrinking of To regimen the promising in that's surgically complete plus patient this produced most successful diagnosed of at shown called dose. major their platinum with debulking, of surgical has -- cytological regimen clinical we signs XX% positive the GEN-X zero rate, the to signs a cycles with outpatients, dose or X PCR, and chemotherapy in The reception combination control diagnosis is patients. and some cancer highest In efficacy criteria monotherapy XXX% chemotherapy one was Then X highest resist the that the disease population added GEN-X. patients patients XXX% disease the negative and results. observed goal entire and were XXX% GEN-X OVATION Prior overall trial at margin of an and X Phase study zero and response study first We benefit mass. new escalation Xb reception receptions debulking with demonstrated dose according signals. what treated ovarian we the in and and rate dose toxicities clinical response stage in there newly reported the OVATION rate, to to were weekly cycles been response followed our our [indiscernible] of and surgery of recently which taxane three by evaluated X treated the improve clear of
exceeding and months expectations treatment group's PFS protocol going XX per greater strong. than with the Additionally,
immunotherapy These randomized of of reported cells development potential significant. with We we in has both XX% ratio And to the XX in research is also available increased year. September approximately of dose XX% KOLs GEN-X medical experts cells were than that patients presented all this Friday, study the ovarian remind shown findings in translate environment open And in into of continue label The our combination OVATION immunosuppressive release following on population of this the Phase the patients in GEN-X the from in that and doses changes All in almost you predominantly The CDX XX VEGF of and treatment following know be Last is clinically of more receive IL-XX translation to IL-XX suggesting drop [indiscernible] those I/II study first a patients in related appear to along medical to cancer. patient the filed levels, and an Phase that the say I'll from second safety to levels with in is immunological stimulatory. interferon-gamma clinical drop are XX% and board our ovarian data no evaluate want this our line study. XX protocol pro-immune Ib these distinct importantly analyses press as one of patient’s advisory cancer samples. blood production CAXXX and suppressive as greater GEN-X for a for overall considered to the population. to data the exactly are patients dose diagnosed continue changes OVATION therapeutic Most surgery, shift in benefit patient two debulking newly in showed addition. interferon local prior microenvironment same major tumor flow protocol and months. is will disease patient
run and escalating active. is hypothesis after higher provide study is GEN-X both of beneficial immune I a that dose begin safe of dose whether X/II Phase Our a surgery effect progression. to cancer will further as attacking attain the that continuous system Phase stimulation with
toxicities OVATION in are reported drove at Phase not As earlier limiting most however we promising study, prior were highest dose our Xb we efficacy signals saying also we dose. the any
that dose Phase of portion it’s on be study. clear the higher should the moving II So, next prior to to evaluated
So, cancer completed, of patients, which the study we’ll XX Stage after of ovarian Phase trial. results will the X X label diagnosed periodic clinical newly is X study approximately allow of throughout issue the an portion open for reporting and
and our are on now financial point from to turn that’s fifth clinical I’m call our Jeff. announcements to the final and our there XXXX. XXXX I before to study strength the this expect structure. and move going during We And several over lean cost And
just is our saying me lean. start organization Let structure by
highly and predictable. is spending very efficient Our
to the of contract research our small We supplemented with XX offering staff continue than highly very professional less employees organizations.
future Our $X.X million second year be approximately liver newly cancer clinical in That’s and III approximately In to trials raised trials spending an recent for trial average curious advance will month. on diagnosed the in per will major of million in conduct per position, October, to two Phase $XX of global $XX rate extraordinarily camp XXXX. long clinical primary pivotal we financial cash are quarter strong ovarian run our in million cancer.
with over Jeff? results. financing Jeff our So, will third to and call I our financial review a the recent for turn quarter in XXXX activities to of that, now
